ArticleScience translational medicine2024
Placental senescence pathophysiology is shared between peripartum cardiomyopathy and preeclampsia in mouse and human.
Article in Science translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 24 citations in OpenAlex.
- The pathophysiology of pre-eclampsia.Nature reviews. Nephrology · 2026Review
- Ex Vivo Perfusion Unmasks a Proteomic Signature of Primary Graft Dysfunction in Donor Hearts.JACC. Heart failure · 2026Article
- CD38-activated macrophages drive age-related placental senescence by depleting NADNature communications · 2026Article
- Placental Senescence: An Emerging Target for Precision Obstetrics.The journal of obstetrics and gynaecology research · 2026Article
- Advancing Human Placental Modeling Through Stem-Cell-Derived Trophoblast Organoids and Reprogramming Innovations.Biomedicines · 2026Review
- Heart failure in the elderly: epidemiology, mechanisms, and management.European heart journal · 2026Review
- Large-scale proteomics in early pregnancy and timing of onset of hypertensive disorders of pregnancy.medRxiv : the preprint server for health sciences · 2026Article
- Immunological consequences of senescence in physiology and pathology.Journal of translational medicine · 2026Review
- Role of Senescence in the Pathophysiology of Preeclampsia and Future Health.Hypertension (Dallas, Tex. : 1979) · 2026Review
- Targeting the GSK-3β/mTOR axis: a novel pharmacological strategy for preeclampsia prevention and treatment.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Elevated Activin-A serum levels in patients with acute peripartum cardiomyopathy and during left ventricular recovery.ESC heart failure · 2026Observational
- Cardiovascular complications of pregnancy.The Journal of clinical investigation · 2026Review
- The SIRT1-p53 axis drives a ferro-aging-like program and aggravates trophoblast dysfunction in preeclampsia.Frontiers in aging · 2026Article
- Natural Products as Anti-Senescence-Associated Secretory Phenotype (SASP) Agents.Current medicinal chemistry · 2026Review
- Premature placental senescence in early-onset preeclampsia: syncytiotrophoblast SASP and the maternal syndrome.Frontiers in public health · 2026Review
- Integrative bioinformatics analysis identifies placental senescence-associated signatures in early-onset preeclampsia.Frontiers in endocrinology · 2026Article
- Venoarterial extracorporeal membrane oxygenation for peripartum cardiomyopathy complicated by severe preeclampsia: a case report with 5-year follow-up.Frontiers in medicine · 2026Article
- Multi-omic insights of preeclampsia and cardiovascular health outcomes.Communications medicine · 2025Review
- Reprogramming cellular senescence and aging clocks for advanced cancer immunotherapy.Molecular cancer · 2025Review
- Aims and Rationale of a National Registry Integrating Clinical, Echocardiographic, and Multi-Omics Profiling to Promote Precision Medicine in Peripartum Cardiomyopathy.Biomedicines · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors at 16 institutions in 4 countries.
Funding
Abstract
Peripartum cardiomyopathy (PPCM) is an idiopathic form of pregnancy-induced heart failure associated with preeclampsia. Circulating factors in late pregnancy are thought to contribute to both diseases, suggesting a common underlying pathophysiological process. However, what drives this process remains unclear. Using serum proteomics, we identified the senescence-associated secretory phenotype (SASP), a marker of cellular senescence associated with biological aging, as the most highly up-regulated pathway in young women with PPCM or preeclampsia. Placentas from women with preeclampsia displayed multiple markers of amplified senescence and tissue aging, as well as overall increased gene expression of 28 circulating proteins that contributed to SASP pathway enrichment in serum samples from patients with preeclampsia or PPCM. The most highly expressed placental SASP factor, activin A, was associated with cardiac dysfunction or heart failure severity in women with preeclampsia or PPCM. In a murine model of PPCM induced by cardiomyocyte-specific deletion of the gene encoding peroxisome proliferator-activated receptor γ coactivator-1α, inhibiting activin A signaling in the early postpartum period with a monoclonal antibody to the activin type II receptor improved heart function. In addition, attenuating placental senescence with the senolytic compound fisetin in late pregnancy improved cardiac function in these animals. These findings link senescence biology to cardiac dysfunction in pregnancy and help to elucidate the pathogenesis underlying cardiovascular diseases of pregnancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.